Press Releases

Driving digitization forward in hospitals requires product solutions based on RFID technology. Schreiner MediPharm supports this trend with a product evolution and equips its tamper-evident specialty label “Cap-Lock” with an RFID inlay. The security concept for prefilled syringes consisting of a label and cap adapter now also enables automated inventory and supply chain management as well as digital first-opening indication. Cap-Lock plus RFID thus offers efficient and reliable pr

Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, announced a clinical collaboration agreement with Novartis to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with each of Kisqali® (ribociclib) and Piqray® (alpelisib) in patients with recurrent, locally advanced or metastatic estrogen receptor-pos

Y-mAbs Therapeutics, Inc.  a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for 177Lu-omburtamab-DTPA for the treatment of B7-H3 positive Central Nervous System (“CNS”) and Leptomeningeal Metastas

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced initial safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. These early data demonstrate proof of mechanism in patients with advanced solid tumors and establish a max

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designations (ODD) for KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM). Both orphan diseases are autoimmune inflammatory myopathies that are chronic and debilitating diseases characterized by marked morbidity and mortality. The

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of multi-drug resistant infectious diseases, announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank™. APT’s PhageBank is a continually expanding phage library deployed with a companion diagnostic to achieve rapid response and cost-

Aerogen , the world leader in aerosol drug delivery systems, announced the details of a large collaborative effort to support pharmaceutical companies around the world as they work to develop COVID-19 treatments and vaccines. The original text of this announcement, written in the source language, is the authentic official version. Translations are offered solely for the convenience of the reader and must refer to the original text, which is the only legally valid text.

ProBioGen AG Berlin, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, & Heidelberg Pharma AG, Ladenburg, Germany, today announced that Heidelberg Pharma has signed a Master Service Agreement for the antibodies used in two of their pipeline Antibody Targeted Amanitin Conjugate (ATAC) molecules. Under the agreement, ProBioGen is conducting the full service package from cell line development using its CHO.RiGHT® cell line expressio

Valicare GmbH, a wholly owned subsidiary of Syntegon,now offers additional services along the entire product life cycle of pharmaceutically and biotechnologically produced drugs. A new focus is on consulting services for the transition of products from the development phase to the GMP compliant manufacturing of investigational medicinal products.These services are complemented by the presentation and assessment of market-specific requirements, investigational drug management and the necessary

The Salk Institute and BridgeBio Pharma, Inc. announced a three-year collaboration agreement formed to advance cutting-edge academic discoveries in genetically driven diseases toward therapeutic applications. Under the partnership, BridgeBio will help fund research programs from Salk’s world-renowned innovative cancer research, with the eventual goal of developing new therapeutics for patients in need. “Salk is known for its outstanding research, in particular in the fie